Recurrent macroscopic hematuria in a pediatric patient: is it early to diagnose as having type I hereditary C2 deficiency?


Journal

CEN case reports
ISSN: 2192-4449
Titre abrégé: CEN Case Rep
Pays: Japan
ID NLM: 101636244

Informations de publication

Date de publication:
11 2020
Historique:
received: 14 02 2020
accepted: 23 04 2020
pubmed: 7 5 2020
medline: 7 9 2021
entrez: 7 5 2020
Statut: ppublish

Résumé

Hereditary C2 deficiency is the most common early complement deficiency and characterized by recurrent infections and autoimmunity despite most patients are also asymptomatic. Type I hereditary C2 deficiency is caused by a heterozygous deletion in C2 gene resulting in early stop codon and lack of C2 production. Clinical spectrum may vary and pure nephrological involvement without the presence of recurrent infections is scarce in hereditary C2 deficiency.We report here a previously healthy 14-year-old boy presenting recurrent self-limited macroscopic hematuria and persistently low serum C4 levels, diagnosed as having type I hereditary C2 deficiency with confirming a novel heterozygote deletion (c.1567 + 22_1567 + 43del) in C2 gene. He has been remained asymptomatic for the next 18 months. Since the diagnosis of C2 deficiency was made in the absence of organ-threatening involvement such as immune complex-mediated glomerulonephritis, we think that early diagnosis and optimal follow-up may improve life-span of the patients with hereditary early complement deficiencies.

Identifiants

pubmed: 32372346
doi: 10.1007/s13730-020-00487-5
pii: 10.1007/s13730-020-00487-5
pmc: PMC7502104
doi:

Substances chimiques

Complement C2 0
Complement C4 0

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

344-346

Références

J Clin Immunol. 2003 Jul;23(4):297-305
pubmed: 12959222
Pediatr Rheumatol Online J. 2015 Nov 21;13:51
pubmed: 26590091
Vaccine. 2008 Dec 30;26 Suppl 8:I28-33
pubmed: 19388161
Front Immunol. 2016 Feb 24;7:55
pubmed: 26941740
Arthritis Care Res (Hoboken). 2011 Mar;63(3):454-9
pubmed: 20890976
Mol Immunol. 2006 Jan;43(1-2):78-85
pubmed: 16026838
N Engl J Med. 2001 Apr 5;344(14):1058-66
pubmed: 11287977
Ann Rheum Dis. 1986 May;45(5):428-30
pubmed: 3718019
Expert Rev Clin Immunol. 2008 Sep;4(5):629-37
pubmed: 20476965
Croat Med J. 2013 Dec;54(6):569-73
pubmed: 24382852
Am J Med. 1977 May;62(5):765-71
pubmed: 860727
J Clin Immunol. 2020 May;40(4):576-591
pubmed: 32064578
J Rheumatol. 1994 Jun;21(6):1128-33
pubmed: 7932427

Auteurs

Rabia Miray Kisla Ekinci (RM)

Department of Pediatric Rheumatology, Faculty of Medicine, Cukurova University, Saricam, Adana, 01331, Turkey. mir_kisla@hotmail.com.

İbrahim Altun (İ)

Department of Pediatrics, Faculty of Medicine, Cukurova University, Adana, Turkey.

Atil Bisgin (A)

Department of Medical Genetics, Faculty of Medicine, Cukurova University, Adana, Turkey.

Bahriye Atmis (B)

Department of Pediatric Nephrology, Faculty of Medicine, Cukurova University, Adana, Turkey.

Derya Ufuk Altintas (DU)

Department of Pediatric Allergy and Immunology, Faculty of Medicine, Cukurova University, Adana, Turkey.

Sibel Balcı (S)

Department of Pediatric Rheumatology, Faculty of Medicine, Cukurova University, Saricam, Adana, 01331, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH